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Tumor suppressor genes 
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What is a Tumor Suppressor Gene? 
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 A tumor suppressor gene is a type of cancer gene 
that is created by loss-of function mutations. 
  In contrast to the activating mutations that generate 
oncogenic alleles from proto-oncogene precursors, 
tumor suppressor genes, and the proteins they 
encode, are functionally inactivated by mutations. 
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 Tumor suppressor genes typically control processes 
fundamental to the maintenance of stable tissue 
compartments.  
 
 These processes include: 
1. The maintenance of genetic integrity 
2. The progression of the cell cycle 
3.  Differentiation 
4. Cell–cell interactions 
5. Apoptosis 
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 The first cancer genes to be discovered were oncogenes. For a 
time it was widely believed that the cancer phenotype resulted 
primarily from activating mutations that led to gains of 
function. An early piece of evidence that other types of genetic 
alteration might also be important in cancer was provided by 
Henry Harris and his colleagues. 
 In a 1969 study, Harris adopted a novel approach to study the 
genetic factors that were involved in cancer cell phenotypes. 
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Retinoblastoma and Knudson’s Two-Hit 
Hypothesis 
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Loss of Heterozygosity 
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 One of the key observations that guided the 
discovery of the RB gene and confirmed its 
recessive nature was LOH, the reduction to 
homozygosity of a locus that previously was 
heterozygous. LOH is the second ‘hit’ 
predicted by Knudson, and represents the 
loss of the remaining wild type allele of a 
recessive tumor suppressor gene. With 
current methods, LOH can readily be 
assessed by the examination of known single 
nucleotide polymorphisms (SNPs), which 
provide convenient and easily detectable 
genetic markers. 
 
Mechanisms of LOH 
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 Loss of a whole chromosome 
 Mitotic recombination 
 Localized mutations 
These processes 
occur at a higher 
rate in some 
cancer cells than 
they do in normal 
cells. 
Correspondingly, 
the rate of tumor 
suppressor gene 
loss is frequently 
higher in cancer 
cells than in pre-
cancerous 
precursors. 
Recessive Genes, Dominant Traits 
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 Individuals are strongly predisposed to 
retinoblastoma if they inherit a single defective RB 
allele.  
 In general, while tumor suppressor genes are 
recessive, the inheritance of a mutation in a tumor 
suppressor gene confers cancer susceptibility, which 
is a dominant trait. 
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P53 Inactivation: A Frequent 
Event in Tumorigenesis 
13 
 Subsequent analysis of P53 genes in large numbers of tumors revealed 
that loss of P53 is a frequent event in human cancers. A significant 
proportion of tumors arising in many different tissues carry somatic 
mutations that inactivate P53. Among tumors in which P53 mutations are 
prevalent are some of the most common forms of cancer. Overall, P53 is 
mutated in about half of all human cancers. 
14 
 In contrast to RB, which tends to 
be inactivated by large deletions, 
P53 is typically inactivated by 
small alterations. A smaller 
proportion of mutations 
inactivate P53 by truncating the 
open reading frame, either by a 
nonsense point mutation or by a 
small insertion or deletion that 
causes a frameshift.  
 In some cancer types, specific 
mutations in P53 can be 
correlated with environmental 
mutagens. Ultraviolet radiation, 
food-borne toxins, and cigarette 
smoke have all been found to 
leave highly characteristic 
mutations in P53. 
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 In a significant number of cancers, P53 is 
inactivated not by mutation, but by the activation of 
an antagonistic oncogene.  
 This form of inhibition occurs at the 
posttranslational level and is mediated by protein–
protein interactions. 
 
Functional Inactivation of p53: Tumor 
Suppressor Genes and Oncogenes Interact 
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Two highly illustrative oncoproteins that inhibit p53 
and contribute to tumorigenesis: 
 
 Mdm2 
 
 Human papillomavirus oncoprotein E6 (HPV E6) 
Mdm2 
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 MDM2 is a proto-oncogene that was originally found in double minutes in 
tumorigenic mouse cells. The human homolog (sometimes called Hdm2) is an 
enzyme that covalently modifies proteins by the addition of ubiquitin. 
  The ubiquitination of proteins by ubiquitin ligases like Mdm2 serves to target those 
proteins for degradation by the proteosome. Thus, the interaction of p53 with 
Mdm2 leads to p53 degradation, keeping p53 protein levels within a narrow range of 
intracellular concentration. In several types of cancers, principally soft-tissue 
sarcomas, the MDM2 gene is amplified. The increased levels of Mdm2 are 
oncogenic, causing decreased levels of p53 and resulting in a loss of p53 function. 
 MDM2 is amplified in roughly one third of sarcomas. The MDM2 locus is often 
amplified 50-fold or greater in these cancers. 
HPV E6 
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 A second oncogene that affects p53 is not a cellular 
gene, but rather is a viral introduced upon infection 
by the human papillomaviruses (HPV). While the 
vast majority of cancers arise solely as a result of 
germline and/or somatically acquired mutations, an 
atypical exception is cancer of the uterine cervix. In 
the majority of cervical cancers, p53 is functionally 
inactivated by the inhibitory binding of an HPV-
encoded protein known as E6. 
Germline Inheritance of Mutant P53 
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Li–Fraumeni Syndrome 
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 LFS was first recognized as a clinical entity by 
Frederick Li and Joseph Fraumeni, in 1969. 
 P53 mutant alleles are found in the germline of 
individuals with an inherited susceptibility to cancer 
known as Li Fraumeni syndrome (LFS).  
 LFS is an autosomal dominant disorder mainly 
characterized by the early onset of bone or soft tissue 
sarcomas. 
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 The patterns of cancer that occur in LFS patients are 
partially dependent on the precise P53 mutation 
inherited.  
 Mutations within the exons that encode the DNA 
binding domain of p53 are associated with a higher 
prevalence of brain tumors and an earlier onset of 
breast cancers, whereas mutations outside the DNA-
binding domain are associated with a higher 
incidence of adrenal cancers. 
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Relative risk 
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  All human beings are at risk of cancer. In kindreds 
with germline tumor suppressor gene mutations, 
that risk is elevated. For a given cancer, the relative 
risk (also known as the risk ratio) compares the 
probability of cancer in two groups and is defined as: 
 
 Relative risk = Absolute risk of cancer in carriers (%) / 
Absolute risk of cancer in the general population (%) 
Odds ratio 
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 Another comparison of risk between two cohorts is the odds ratio. Most 
often applied to case-control studies in which the outcome (i.e. cancer) is a 
rare occurrence, the odds ratio compares the relative odds of cancer 
between two groups. Applied to the analysis of carriers of a specific allele: 
 Odds ratio = 
Odds against developing cancer in the general 
population / Odds for developing cancer in carriers 
 
 As an example, consider a hypothetical cancer-causing allele that has a 
penetrance of 10%. If the incidence of the same cancer in the general 
population is 1%, the relative risk is 0.10/0.01 = 10. In contrast, the odds 
ratio would be (99 to 1)/(1 in 10) = 99/0.1 = 990. In general, the relative 
risk yields a more intuitive result than an odds ratio, but can lead to 
misleading results if applied to studies in which only the outcome is 
measured. 
Breast Cancer Susceptibility: BRCA1 and 
BRCA2 
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Most Tumor Suppressor 
Genes are Tissue-Specific 
Inherited Tumor Suppressor Gene Mutations 
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 Caretakers: encode products that stabilize the genome. Fundamentally, 
mutations in caretaker genes lead to genimic instability. Tumor cells arise from two 
distinct classes of genomic instability: mutational instability arising from changes in the 
nucleotide sequence of DNA and chromosomal instability arising from improper 
rearrangement of chromosomes. 
 
 Gatekeepers: encode gene products that act to prevent growth of potential 
cancer cells and prevent accumulation of mutations that directly lead to increased 
cellular proliferation 
 
  Landscapers: encode products that, when mutated, contribute to the 
neoplastic growth of cells by fostering a stromal environment conducive to unregulated 
cell proliferation. 
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 Inactivated APC alleles are highly penetrant while inactivated 
SMAD4 alleles are less so. 
 Classical growth-controlling tumor suppressor genes such as APC 
have been categorized as ‘gatekeepers’. Gatekeepers directly 
suppress cell outgrowth. Cells that lose gatekeeper activity form 
neoplasia, each of which has the potential to become a cancer. 
When wild type gatekeeper genes are experimentally reintroduced 
into established cancer cells, they typically lead to suppression of 
growth. 
 The inherited mutations of SMAD4 affect epithelial cell populations 
in a less direct manner. Germline SMAD4 mutations appear to 
primarily alter the growth of stromal cells that are not cancer 
precursors. SMAD4 inactivation thus alters the tissue structure of 
the colorectum. This abnormal microenviroment provides a fertile 
landscape for the outgrowth of epithelial neoplasia. Mutations in 
SMAD4 typify what has been termed a ‘landscaper’ defect. 
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 RB clearly functions as a gatekeeper in the cells of the 
developing retina. 
 In contrast, the timing of P53 inactivation in later stages 
of colorectal cancer suggests that P53 does not function 
as a gatekeeper in the colorectal epithelium.  
 However, a significant body of evidence suggests that 
P53 is a gatekeeper in other cancer types, most notably 
breast cancers. 
 Examples of caretaker genes are BRCA1 and BRCA2, 
breast cancer susceptibility genes that are required for 
DNA repair 
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